Cerapedics Inc. successfully treated the first U.S. patient using its newly approved bone graft designed to accelerate lumbar fusion. This marks a significant milestone following the approval from the U.S. Food and Drug Administration (FDA) for the PearlMatrix P-15 Peptide Enhanced Bone Graft.
The procedure was carried out at AdventHealth Avista in Louisville, Colo., by Dr. Sharad Rajpal, medical director of the Advanced Spine Program. The PearlMatrix Bone Graft aims to enhance recovery for patients suffering from degenerative disc disease. It is the first drug-device combination product specifically approved for this application.
Having received FDA premarket approval in June 2025, PearlMatrix is positioned as a pioneering solution among the over 350 spinal bone grafts available in the U.S. market. Westminster-based Cerapedics has two of only three spinal bone grafts that have successfully navigated the approval process.
“This first surgery post-approval is a significant milestone for Cerapedics,” said Valeska Schroeder, CEO of Cerapedics. “Every single team member behind the development, approval and distribution of PearlMatrix P-15 Peptide Enhanced Bone Graft worked tirelessly to get this unique drug-device into the hands of surgeons to help them safely and effectively treat their patients.”
